- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00809627
Caffeine Versus Placebo for Spinal Headaches
August 12, 2025 updated by: United States Naval Medical Center, Portsmouth
A Prospective Trial of IV Caffeine vs Placebo for Post-Dural-Puncture Headache in the Emergency Department
Caffeine will be studied against placebo in patients with positional headache after a lumbar puncture (aka "spinal headache").
Study Overview
Status
Withdrawn
Conditions
Intervention / Treatment
Detailed Description
Pain will be assessed at set intervals using a Visual Analog Scale.
Blood patch therapy will be offered to all those still in pain at the end of one hour after drug administration.
Study Type
Interventional
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Virginia
-
Portsmouth, Virginia, United States, 23708
- Emergency Department, Naval Medical Center Portsmouth
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 50 years (Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- diagnosed with post dural puncture headache
Exclusion Criteria:
- age < 18
- pregnant
- allergic to caffeine
- cardiac or peripheral vascular disease
- uncontrolled hypertension
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: 1
IV caffeine with saline and opiate
|
Caffeine 500 mg IV
Other Names:
|
|
Placebo Comparator: 2
IV saline with opiate
|
Normal saline
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Pain as measured by Visual Analog Scale
Time Frame: 60 minutes
|
60 minutes
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Study Chair: Mark A Kostic, MD, United States Naval Medical Center, Portsmouth
- Principal Investigator: Marcelo Darabos, MD, United States Naval Medical Center, Portsmouth
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
January 1, 2007
Primary Completion (Actual)
May 1, 2008
Study Completion (Actual)
May 1, 2008
Study Registration Dates
First Submitted
December 16, 2008
First Submitted That Met QC Criteria
December 16, 2008
First Posted (Estimated)
December 17, 2008
Study Record Updates
Last Update Posted (Actual)
August 15, 2025
Last Update Submitted That Met QC Criteria
August 12, 2025
Last Verified
August 1, 2025
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pain
- Neurologic Manifestations
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Headache Disorders
- Headache Disorders, Secondary
- Headache
- Post-Dural Puncture Headache
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Neurotransmitter Agents
- Purinergic Antagonists
- Purinergic Agents
- Central Nervous System Stimulants
- Phosphodiesterase Inhibitors
- Purinergic P1 Receptor Antagonists
- Caffeine
Other Study ID Numbers
- CIP 2006 0051
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.